Source-grounded facts extracted from P3 Health Partners Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
P3 Health Partners Inc. shareholders approved Approval, in accordance with Nasdaq Listing Rule 5635(d), the issuance of up to 3,341,130 shares of Class A common stock upon the exercise of outstanding Class A common stock warrants held by VBC Growth SPV 5, LLC. at the 2026-06-09 meeting.
“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
P3 Health Partners Inc. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers. at the 2026-06-09 meeting.
“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
P3 Health Partners Inc. shareholders approved Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-09 meeting.
“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
P3 Health Partners Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2029, and until their respective successors have been duly elected and qualified. at the 2026-06-09 meeting.
“On June 9, 2026, P3 Health Partners Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”).”
P3 Health Partners Inc. received a nasdaq compliance regained notice regarding market value (rules 5550(b)(2)).
“May 20, 2026, the Company received a letter from the Staff notifying the Company that, based on the Company’s Form 8-K filed with the SEC on May 15, 2026, the Staff has determined that the Company complies with Nasdaq Li”
P3 Health Partners Inc. reported financial results for the first quarter ended March 31, 2026.
“On May 14, 2026, P3 Health Partners Inc. (the "Company") announced its financial results for the three months ended March 31, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Report").”
P3 Health Partners Inc. reported financial results for the fourth quarter ended December 31, 2025.
“P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its financial results for the fourth quarter and full year ended December 31, 2025, and provided 2026 guidance.”
P3 Health Partners Inc. reported financial results for the year ended December 31, 2025.
“On March 26, 2026, P3 Health Partners Inc. (the “Company”) announced its financial results for the year ended December 31, 2025.”
P3 Health Partners Inc. entered into Statement of Work with a large nonprofit health insurance provider in the state of Nebraska (effective 2026-03-19).
“Effective as of March 19, 2026, P3 Health Partners, LLC (the “Company”) entered into a Statement of Work (the “SOW”) with a large nonprofit health insurance provider in the state of Nebraska (the “Client”), which incorporates the terms of a Master Services Agreement between the parties (the (the “MSA,” and together with the SOW, the “Agreements”).”
P3 Health Partners Inc. amended Amendment to Unsecured Promissory Note with VBC Growth SPV 5, LLC valued at $19.0 million (effective 2026-02-11).
“On February 11, 2026, P3 Health Group, LLC (the “Company”) entered into an Amendment to Unsecured Promissory Note (the “Amendment”) with VBC Growth SPV 5, LLC (the “Holder”) amending the terms of the Unsecured Promissory Note originally dated May 29, 2025 (the “Note). The Amendment modifies Section 1, clause (a)(iii) of the Note to extend the availability period for the third tranche of funding. Under the Amendment, the remaining $19.0 million of the third tranche is available for one or more draws through June 30, 2026.”
P3 Health Partners Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 21, 2025, P3 Health Partners Inc. (the “Company”) received a letter (the “Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it does not presently comply with Nasdaq’s Listing Rule 5550(b)(1) (the “Listing Rule”), which requires that the Company maintain a minimum of $2.5 million in stockholders’ equity, and that the Company also does not meet the alternatives of market value of listed securities or net income from continuing operations set forth in the Listing Rule. The Letter does”
P3 Health Partners Inc. incurred loan of up to $70.0 million with VBC Growth SPV 5, LLC at 19.5% per annum maturing August 13, 2028.
“independent, disinterested directors of the Company. VBC 5 Promissory Note The Promissory Note was issued by P3 LLC to VBC 5 on May 29, 2025, and provides for funding of up to $70.0 million (the “Promissory Note”), available for draw by P3 LLC in tranches, as follows: (i) a first tranche of $15.0 million available to P3 LLC upon the Effective Date, (ii) a second”
P3 Health Partners Inc.: Filed Certificate of Amendment to effect a 1-for-50 reverse stock split of common stock, effective April 11, 2025 (effective 2025-04-11).
“On April 11, 2025, P3 Health Partners Inc., a Delaware corporation (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Charter Amendment") with the Secretary of State of Delaware to effect a 1-for-50 reverse stock split (the "Reverse Stock Split") of the Company's outstanding Class A common stock, $0.0001 par value per share (the “Class A common stock”), and Class V common stock, $0.0001 par value per share (the “Class V common stock,” and together with the Class A common stock, the “common stock”). The Reverse Stock Split became effective at 5:00 p.m. Eastern Time on April 11, 2025 (the “Effective Time”).”
P3 Health Partners Inc. incurred loan of $30.0 million with VBC Growth SPV 4, LLC at 19.5% per annum maturing August 13, 2028.
“disinterested directors of the Company. VBC 4 Promissory Note The Promissory Note was issued by P3 LLC to VBC 4 on February 13, 2025, and provides for funding of up to $30.0 million (the “Promissory Note”), available for draw by P3 LLC in two tranches, as follows: (i) a first tranche of $15.0 million available to P3 LLC upon the Effective Date, and (ii) a”
Atul Kavthekar resigned as Chief Financial Officer at P3 Health Partners Inc..
“Mr. Pedersen will succeed Atul Kavthekar, who resigned from his position as Chief Financial Officer of the Company effective as of the Effective Date.”
Leif Pedersen was appointed as Chief Financial Officer at P3 Health Partners Inc..
“On August 29, 2024, the Board of Directors (the “Board”) of P3 Health Partners Inc. (the “Company”) appointed Leif Pedersen as Chief Financial Officer of the Company, effective as of October 1, 2024 (the “Effective Date”).”
Sherif Abdou was appointed as Vice Chairperson of the Board and Senior Advisor at P3 Health Partners Inc..
“the Board appointed Dr. Abdou as Vice Chairperson of the Board. Dr. Abdou will serve as Senior Advisor to the Company’s board of directors and Chief Executive Officer”
Sherif Abdou resigned as Chief Executive Officer and President at P3 Health Partners Inc..
“Dr. Coffman succeeds Sherif Abdou, M.D., who resigned from his positions as Chief Executive Officer and President of the Company effective as of the Effective Time.”
Aric Coffman was appointed as Chief Executive Officer and President at P3 Health Partners Inc..
“appointed Aric Coffman, M.D. as Chief Executive Officer and President of the Company, effective at 12:00 p.m. Eastern Time on May 8, 2024”
P3 Health Partners Inc. updated its first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 8, 2024, P3 Health Partners Inc. (the “Company”) announced its financial results for the three months ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Report”).”
P3 Health Partners Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $346.9 million, net income Net loss was $69.1 million. Guidance reaffirmed.
“for the P3 model is as high as ever and that our demonstrated ability to bend the cost curve is driving this demand.” Fourth Quarter 2023 Financial Results • Total revenue was $346.9 million, an increase of 34% compared to $258.2 million in the fourth quarter of the prior year • Capitated revenue was $342.8 million, an increase of 35% compared to $254.0 million in”
P3 Health Partners Inc. incurred loan of up to $25.0 million with VBC Growth SPV 2, LLC at 17.5% per annum maturing September 30, 2027.
“of independent, disinterested directors of the Company. Promissory Note The Promissory Note was issued by P3 LLC to VBC 2 on March 22, 2024, and provides for funding of up to $25.0 million, available for draw by P3 LLC in two tranches, as follows: (i) a first tranche of $10.0 million available to P3 LLC upon the Effective Date, and (ii) a second tranche of $15.0”
P3 Health Partners Inc.: Board adopted amended and restated bylaws with changes related to universal proxy rules, stockholder nomination and proposal disclosures, and proxy card color requirements, effective March 8, 2024 (effective 2024-03-08).
“On March 8, 2024, the Board of Directors (the “ Board ”) of P3 Health Partners Inc., a Delaware corporation (the “ Company ”), approved and adopted amendments to the Company’s bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.”
P3 Health Partners Inc. reported Full-Year 2024 results: revenue $1.45 billion to $1.55 billion. Guidance initiated.
“Providing full-year 2024 guidance: • Medicare Advantage Members from 125,000 to 135,000 • Revenue from $1.45 billion to $1.55 billion • Medical Margin from $230 million to $250 million • Medical Margin PMPM from $165 to $175 • Adjusted EBITDA from $20 million to $40 million, as previously announced”
P3 Health Partners Inc. reported Full-Year 2023 results: revenue $1.2 billion to $1.25 billion. Guidance reaffirmed.
“Reaffirming full-year 2023 guidance : • Medicare Advantage Members from 115,000 to 120,000 • Revenue from $1.2 billion to $1.25 billion • Medical Margin from $155 million to $175 million • Medical Margin PMPM from $120 to $130 • Adjusted EBITDA is expected to be a loss between $50 million and $30 million”
P3 Health Partners Inc. amended Registration Rights Amendment and Waiver with certain of its stockholders (effective 2023-11-08).
“On November 8, 2023, P3 Health Partners Inc. (the “Company”) and certain of its stockholders (representing a majority of the registrable securities under the Registration Rights Agreement (as defined below)) entered into an amendment and waiver (the “Registration Rights Amendment and Waiver”) to the Registration Rights Agreement, dated as of April 6, 2023 (the “Registration Rights Agreement”), by and among the Company and the stockholders party thereto.”
P3 Health Partners Inc. reported three and nine months ended September 30, 2023 results: revenue $288.4 million, net income Net loss was $37.3 million. Guidance reaffirmed.
“preliminary 2024 full-year Adjusted EBITDA guidance of $20 million to $40 million,” said Dr. Sherif Abdou, CEO of P3. Third-Quarter 2023 Financial Results • Total revenue was $288.4 million, an increase of 16% compared to $248.3 million in the third quarter of the prior year. Net loss was $37.3 million, an increase of approximately 43% compared to a net loss of”
P3 Health Partners Inc. reported the three months ended June 30, 2023 results: revenue $325.6 million, net income Net loss was $27.6 million. Guidance reaffirmed.
“ability to bend the cost curve for our patients, providers, and payor clients,” said Bill Bettermann, COO of P3. Second-Quarter 2023 Financial Results • Capitated revenue was $325.6 million, an increase of 21.9% compared to $267.1 million in the second quarter of the prior year • Net loss was $27.6 million, compared to a net loss of $903.1 million in the second”
P3 Health Partners Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. at the 2023-07-24 meeting.
“Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 247,477,842 162,838 11,454 —”
P3 Health Partners Inc. shareholders approved Election of three Class II directors for a term of office expiring on the date of the annual meeting of stockholders to be held in 2026, and until their respective successors have been duly elected and qualified. at the 2023-07-24 meeting.
“NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Amir Bacchus, M.D. 203,298,421 39,762,923 4,590,790 Mark Thierer 203,495,651 39,565,693 4,590,790 Lawrence B. Leisure 195,927,721 47,133,623 4,590,790”
P3 Health Partners Inc. reported year ending December 31, 2023 results: revenue $ 1,200 $ 1,250. Guidance raised.
“of 250% compared to fourth quarter of 2022 Full-Year 2023 Guidance Year Ended December 31, 2023 Low High Medicare Advantage Members 115,000 120,000 Total Revenues (in millions) $ 1,200 $ 1,250 Medical margin (2) (in millions) $ 155 $ 175 Medical margin (2) PMPM $ 120 $ 130 Adjusted EBITDA (2) Loss (in millions) $ (55) $ (35) (1) Adjusted EBITDA, Adjusted EBITDA”
P3 Health Partners Inc. reported the first quarter ended March 31, 2023 results: revenue $298.7 million, net income $52.4 million.
“a model where we believe the patient, providers, payors and ultimately our shareholders win,” Dr. Abdou concluded. First Quarter 2023 Financial Results • Capitated revenue was $298.7 million, an increase of 11% compared to $269.7 million in the first quarter of the prior year, and an increase of 18% compared to the fourth quarter of 2022 • Net loss was $52.4 million,”
P3 Health Partners Inc. entered into Letter Agreement with Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (“CPF GP III”) (on behalf of the funds of which CPF GP I is the general partner, certain funds of which CPF GP III is the general partner) and/or cert (effective 2023-04-06).
“On April 6, 2023, in connection with the Purchase Agreement, the Company entered into a letter agreement (the “Letter Agreement”) with Chicago Pacific Founders GP, L.P., a Delaware limited partnership (“CPF GP I”), Chicago Pacific Founders GP III, L.P., a Delaware limited partnership (“CPF GP III”) (on behalf of the funds of which CPF GP I is the general partner, certain funds of which CPF GP III is the general partner) and/or certain of their affiliated entities and funds (collectively, the “CPF Parties”).”
P3 Health Partners Inc. entered into Registration Rights Agreement with the Purchasers (effective 2023-04-06).
“On April 6, 2023, in connection with the Purchase Agreement the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers.”
P3 Health Partners Inc. entered into Securities Purchase Agreement with the purchasers named therein (the "Purchasers") valued at aggregate gross proceeds of approximately $89.5 million (effective 2023-03-30).
“P3 Health Partners Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”) on March 30, 2023.”
P3 Health Partners Inc. entered into Securities Purchase Agreement with the purchasers named therein valued at aggregate gross proceeds of approximately $89.5 million (effective 2023-03-30).
“On March 30, 2023, P3 Health Partners Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”).”
P3 Health Partners Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).
“On March 31, 2023, P3 Health Partners Inc. (the “Company” or “P3”) announced its financial results for the three months and full year ended December 31, 2022.”
P3 Health Partners Inc. updated its fiscal year ended December 31, 2022 guidance (reaffirmed).
“expects to report revenue of between $1.025 billion and $1.075 billion”
Atul Kavthekar changed role as Principal Accounting Officer at P3 Health Partners Inc..
“On January 24, 2023, the Board of Directors of the Company designated Atul Kavthekar, the Company’s Chief Financial Officer, as principal accounting officer of the Company, effective as of the Effective Date.”
Erin Darakjian resigned as Chief Accounting Officer at P3 Health Partners Inc..
“Erin Darakjian notified P3 Health Partners Inc. (the “Company”) of her resignation as Chief Accounting Officer of the Company, effective as of January 27, 2023”
P3 Health Partners Inc. updated its full-year 2023 guidance (initiated).
“announcing financial guidance for the full-year 2023”
P3 Health Partners Inc. updated its full-year 2022 guidance (reaffirmed).
“P3 is reaffirming full-year 2022 financial guidance”
P3 Health Partners Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. at the 2022-12-16 meeting.
“Proposal 2 — Ratification of the appointment of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 183,855,371 37,265 884 0”
P3 Health Partners Inc. shareholders approved Election of three Class I directors for a term of office expiring on the date of the annual meeting of stockholders in 2025 and until their respective successors have been duly elected and qualified. at the 2022-12-16 meeting.
“Proposal 1 — Election of three Class I directors for a term of office expiring on the date of the annual meeting of stockholders in 2025 and until their respective successors have been duly elected and qualified. NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Sherif Abdou, M.D. 142,798,336 40,209,287 885,897 Greg Kazarian 142,641,112 40,366,511 885,897 Greg Wasson 139,313,962 43,693,661 885,897”
P3 Health Partners Inc. amended Amendment to Term Loan Agreement with CRG Servicing LLC, as administrative agent and collateral agent (effective 2022-12-13).
“In connection with the transactions described above, P3 LLC entered into an amendment to that certain Term Loan Agreement, dated as of December 3, 2021, by among P3 LLC, as borrower, the subsidiary guarantors party thereto, the lenders from time to time party thereto and CRG Servicing LLC, as administrative agent and collateral agent.”
P3 Health Partners Inc. entered into Subordination Agreement with the Company, CRG Services LLC, and VBC Growth SPV LLC (effective 2022-12-13).
“In connection with the transactions described above, P3 LLC entered into a subordination agreement, dated as of December 13, 2022 (the “Subordination Agreement”), by and among the Company, CRG Services LLC, as administrative agent under the Company’s existing term loan facility (the “Term Loan Facility”) and VBC.”
P3 Health Partners Inc. entered into Warrant Agreement with VBC Growth SPV LLC (effective 2022-12-13).
“In connection with the Promissory Note, on December 13, 2022, P3 LLC and VBC entered into a Warrant (the “Warrant Agreement”).”
P3 Health Partners Inc. entered into Promissory Note with VBC Growth SPV LLC valued at up to $40.0 million (effective 2022-12-13).
“The Promissory Note was issued by P3 LLC to VBC on December 13, 2022, and provides for funding of up to $40.0 million (the “Promissory Note”),”
Erin Darakjian changed role as Chief Accounting Officer at P3 Health Partners Inc..
“succeeding Ms. Darakjian in such role. Ms. Darakjian remains Chief Accounting Officer, Senior Vice President and principal accounting officer of the Company.”
Atul Kavthekar was appointed as Chief Financial Officer at P3 Health Partners Inc..
“On November 27, 2022, the Board appointed Atul Kavthekar to serve as Chief Financial Officer of the Company, effective as of December 12, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.